Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

THERANEXUS reports cash position as of September 30th 2019

15/10/2019
Download PDF File (285 Ko)

THERANEXUS announces its first half 2019 results

26/09/2019
Download PDF File (285 Ko)

A new milestone reached for Theranexus: inclusion of last patient in phase II trial for THN102 in Parkinson’s patients

24/09/2019
Download PDF File (285 Ko)

THERANEXUS announces inclusion of last subject in its phase 1b trial of THN201

17/09/2019
Download PDF File (397 Ko)

THERANEXUS announces the publication of two scientific papers and a presentation at the European pain congress (EFIC) to be held on 3-7 September in Valencia, Spain

02/09/2019
Download PDF File (393 Ko)

THERANEXUS raises approximately 2.2 million euros in a placement reserved to a category of persons 

11/07/2019
Dowload PDF File (615 Ko)

THERANEXUS announces the launch of a capital increase by private placement for a maximum amount of euro 4 million

10/07/2019
Download PDF File (284 Ko)

THERANEXUS reports cash position as of June 30th 2019

08/07/2019
Download PDF File (268 Ko)

Theranexus and Beyond Batten Disease Foundation (BBDF) announce agreement in
principle to develop and market Batten disease drug candidate BBDF 101

27/06/2019
Download PDF File (416 Ko)

THERANEXUS invited to join in the HealthTech Investor Days (HTDI) 24 & 25 June in Paris

20/06/2019
Download PDF File (363 Ko)